Join Now!      Login

Whole Person Wellness Program
 
healthy.net Wellness Model
Skip Navigation Links
 
 
FREE NEWSLETTER
   
   
   
 
Health Centers
Key Services
 
America's Worst Enemy?
What is the leading cause of death in the United States?
Cancer
Auto Accidents
Heart Disease
Perscription Meds

 
 
 What Doctors Don't Tell You: BREAST CANCER-THE UNKINDEST CUT 
 
What Doctors Don't Tell You © (Volume 3, Issue 11)

Just as much confusion and ignorance surrounds what has been referred to in medicalese as adjuvant (just in case) therapies which are used after surgery to prevent cancer from recurring.

These include hormonal therapy with drugs like tamoxifen, an oestrogen agonist, which acts against the body's production of oestrogen, a factor in the growth of some types of breast cancer. There is also chemotherapy, orally or by injection, often used to shrink the cancer first so the breast may remain intact; radiotherapy, which employs an x-ray machine or other types of radiation, including the temporary insertion into the body of radioactive isotopes; and ovarian ablation, a medical euphemism for what amounts to castration ("inactivating" or removing the ovaries) by surgery, radiotherapy or drugs. The rationale here is that by wiping out the ovaries, you prevent the source of oestrogen, which helps to grow the cancer. Ovarian ablation is mainly used on premenopausal women, which means that after the trauma of cancer and surgery some young women also face either an early menopause or indefinite use of hormone replacement therapy, which itself appears to cause breast cancer.

Most of these adjuvant methods are used in conjunction with breast conserving surgery, although tamoxifen is sometimes used alone for women over 50 with early breast cancer.

As with most new medical "advances" tamoxifen was hailed as a breakthrough with very little examination of its long term effects. This followed a study by the Imperial Cancer Research Fund's Cancer Studies Unit at Oxford, which analyzed the results of 133 different breast cancer treatment studies on 75,000 women worldwide. They found that for post menopausal women tamoxifen would prevent the recurrence of cancer in the other breast by 39 per cent. The study also found that tamoxifen helped to avoid recurrence primarily for the first four years after breast cancer but would nearly double a woman's chances of survival for 10 years, and that long term tamoxifen (between two and five years) is "significantly more effective" than shorter regimens.

Several other surprise findings included the fact that chemotherapy for six months could produce the same results as therapy of a year or more. The study also found that ovarian ablation reduced the annual death rate by about one quarter, causing one editorial in The Lancet (11 January 1992) to call for ablation as a "alternative to chemotherapy" in premenopausal women.

In all of this enthusiasm, what haven't been communicated to the public are the considerable, potentially fatal, side effects of tamoxifen. Because the drug is often recommended to be taken for five to 10 years many questions have been raised about its effect upon bone mineral density, cholesterol levels, hormone secretion and the potential to develop other sorts of cancers in places besides the breast.

First of all, we still don't know conclusively whether it works. In a Viewpoint in The Lancet (7 November 1992), Adriane Fugh-Berman of the National Women's Health Network in Washington, DC, and Professor Samuel Epstein of the University of Illinois School of Public Health, an outspoken critic of cancer treatment, pointed out that in the massive Oxford study a "statistically significant reduction in contralateral [other breast] tumours in patients with breast cancer was found in only three of eight studies."

Increasing numbers of endometrial cancer cases have been reported in postmenopausal women who have received tamoxifen for breast cancer. Drs Epstein and Fugh-Berman point out in The Lancet article mentioned above that tamoxifen increases the risk of endometrial cancer about five fold. Tamoxifen patients also experience abnormal vaginal bleeding, hyperplasia (excessive cell formation), polyps and endometriosis (BMJ, 26 October 1991).

CONTINUED      Previous   1  2  3  4  Next   
 Comments Add your comment 

 About The Author
What Doctors Don't Tell You What Doctors Don’t Tell You is one of the few publications in the world that can justifiably claim to solve people's health problems - and even save lives. Our monthly newsletter gives you the facts you won't......more
 
 From Our Friends
 
 
 
Popular & Related Products
 
Popular & Featured Events
Wellness Inventory Certification Training
     September 16-December 16, 2014
     Teleclass, CA USA
 
Additional Calendar Links
 
Stevia Products & Info
 
Dimensions of Wellness
Wellness, Eating, dimension!

Home       Wellness       Health A-Z       Alternative Therapies       Find a Practitioner       Healthy Products       Bookstore       Wellness Inventory
Healthy Kitchen       Healthy Woman       Healthy Man       Healthy Child       Healthy Aging       Wellness Center       Nutrition Center       Fitness Center
Free Newsletter      What Doctor's Don't Tell You      Stevia.com      Discount Lab Tests      First Aid      Global Health Calendar      Privacy Policy     Contact Us
Disclaimer: The information provided on HealthWorld Online is for educational purposes only and IS NOT intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek professional medical advice from your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.
Are you ready to embark on a personal wellness journey with our whole person approach?
Learn More/Subscribe
Are you looking to create or enhance a culture of wellness in your organization?
Learn More
Do you want to become a wellness coach?
Learn More
Free Webinar